These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31728006)

  • 1. Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein.
    Khan E; Mishra SK; Mishra R; Mishra A; Kumar A
    Sci Rep; 2019 Nov; 9(1):16872. PubMed ID: 31728006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
    Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
    ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs).
    Khan E; Biswas S; Mishra SK; Mishra R; Samanta S; Mishra A; Tawani A; Kumar A
    Biochimie; 2019 Aug; 163():21-32. PubMed ID: 31075282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Insights Reveal the Dynamics of the Repeating r(CAG) Transcript Found in Huntington's Disease (HD) and Spinocerebellar Ataxias (SCAs).
    Tawani A; Kumar A
    PLoS One; 2015; 10(7):e0131788. PubMed ID: 26148061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
    Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation.
    Lazzeroni G; Benicchi T; Heitz F; Magnoni L; Diamanti D; Rossini L; Massai L; Federico C; Fecke W; Caricasole A; La Rosa S; Porcari V
    J Biomol Screen; 2013 Oct; 18(9):984-96. PubMed ID: 23562876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA FISH for detecting expanded repeats in human diseases.
    Urbanek MO; Krzyzosiak WJ
    Methods; 2016 Apr; 98():115-123. PubMed ID: 26615955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Prediction of Potential Inhibitors for Targeting RNA CAG Repeats via Molecular Docking and Dynamics Simulation: A Drug Discovery Approach.
    Singh S; Singh S; Joshi D; Mohanty C; Singh R
    J Cell Biochem; 2024 Jul; 125(7):e30611. PubMed ID: 38884365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
    Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
    Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture.
    Zhang X; Abels ER; Redzic JS; Margulis J; Finkbeiner S; Breakefield XO
    Cell Mol Neurobiol; 2016 Apr; 36(3):459-70. PubMed ID: 26951563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PolyQ-independent toxicity associated with novel translational products from CAG repeat expansions.
    Rudich P; Watkins S; Lamitina T
    PLoS One; 2020; 15(4):e0227464. PubMed ID: 32240172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10.
    Yang WY; Gao R; Southern M; Sarkar PS; Disney MD
    Nat Commun; 2016 Jun; 7():11647. PubMed ID: 27248057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
    Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
    Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
    Sugaya K
    Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Small Molecules that Induce the Degradation of Huntingtin.
    Tomoshige S; Nomura S; Ohgane K; Hashimoto Y; Ishikawa M
    Angew Chem Int Ed Engl; 2017 Sep; 56(38):11530-11533. PubMed ID: 28703441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.
    Smith DL; Portier R; Woodman B; Hockly E; Mahal A; Klunk WE; Li XJ; Wanker E; Murray KD; Bates GP
    Neurobiol Dis; 2001 Dec; 8(6):1017-26. PubMed ID: 11741397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.
    Zhang X; Smith DL; Meriin AB; Engemann S; Russel DE; Roark M; Washington SL; Maxwell MM; Marsh JL; Thompson LM; Wanker EE; Young AB; Housman DE; Bates GP; Sherman MY; Kazantsev AG
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):892-7. PubMed ID: 15642944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.